1. Home
  2. MAPS vs ENTX Comparison

MAPS vs ENTX Comparison

Compare MAPS & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo WM Technology Inc.

MAPS

WM Technology Inc.

N/A

Current Price

$0.38

Market Cap

75.5M

Sector

Technology

ML Signal

N/A

ENTX

Entera Bio Ltd.

N/A

Current Price

$1.32

Market Cap

62.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
MAPS
ENTX
Founded
2008
2010
Country
United States
Israel
Employees
449
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
75.5M
62.6M
IPO Year
N/A
2015

Fundamental Metrics

Financial Performance
Metric
MAPS
ENTX
Price
$0.38
$1.32
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
1
Target Price
$2.61
$10.00
AVG Volume (30 Days)
2.9M
184.9K
Earning Date
05-11-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.25
Revenue
N/A
$42,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$6.17
N/A
P/E Ratio
$9.75
$5.32
Revenue Growth
N/A
N/A
52 Week Low
$0.33
$0.91
52 Week High
$1.36
$3.22

Technical Indicators

Market Signals
Indicator
MAPS
ENTX
Relative Strength Index (RSI) 28.17 55.17
Support Level $0.33 $1.17
Resistance Level $0.75 $1.39
Average True Range (ATR) 0.04 0.12
MACD -0.01 0.03
Stochastic Oscillator 7.77 75.81

Price Performance

Historical Comparison
MAPS
ENTX

About MAPS WM Technology Inc.

WM Technology Inc operates an online cannabis marketplace for consumers, together with a comprehensive set of e-commerce and compliance software solutions for cannabis businesses, which are sold to both storefront locations and delivery operators (retailers) and brands in the legalized cannabis markets in states and territories of the United States. Its comprehensive business-to-consumer and business-to-business suite of products affords cannabis retailers and brands of all sizes integrated tools to compliantly run their businesses and to reach, convert, and retain consumers.

About ENTX Entera Bio Ltd.

Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.

Share on Social Networks: